TY - JOUR
T1 - Premixed Insulin Analogue Compared with Basal-Plus Regimen for Inpatient Glycemic Control
AU - Gracia-Ramos, Abraham Edgar
AU - Cruz-Domínguez, María Del Pilar
AU - Madrigal-Santillán, Eduardo Osiris
AU - Morales-González, José Antonio
AU - Madrigal-Bujaidar, Eduardo
AU - Aguilar-Faisal, José Leopoldo
N1 - Publisher Copyright:
© Copyright 2016, Mary Ann Liebert, Inc. 2016.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Background: No previous studies have investigated the use of a premixed insulin analogue in a hospital setting. Objective: To compare the efficacy and safety of treatment with premixed insulin analogue (insulin lispro mix 75/25, LM75/25) with the basal-plus regimen with insulin glargine in hospitalized patients with type 2 diabetes (T2D). Materials and Methods: A randomized clinical trial in hospitalized patients with T2D and glucose >140 mg/dL on admission was performed. A total of 54 patients were randomized to receive insulin LM75/25 or glargine. In both groups, a correction dose of lispro was administered before meals. Insulin dose was adjusted to obtain a mean blood glucose (BG) between 100 and 140 mg/dL. Results: Improvement in the mean BG after the first day of treatment was similar in both groups (P = 0.470). Glycemic control at the end of follow-up was similar between the group with insulin LM75/25 (131.3 ± 28.4 mg/dL) and insulin glargine (143.8 ± 32.5 mg/dL, P = 0.153). The aim of a BG concentration of <140 mg/dL was obtained in 72% of the patients in the premixed insulin analogue group and 56% of patients in the basal-plus group (P = 0.239). There was no difference in the frequency of hypoglycemia between groups (7 vs. 10, P = 0.529). Conclusion: Results of this trial indicate that the use of a premixed insulin analogue is as effective and safe as the basal-plus regimen to achieve glycemic control.
AB - Background: No previous studies have investigated the use of a premixed insulin analogue in a hospital setting. Objective: To compare the efficacy and safety of treatment with premixed insulin analogue (insulin lispro mix 75/25, LM75/25) with the basal-plus regimen with insulin glargine in hospitalized patients with type 2 diabetes (T2D). Materials and Methods: A randomized clinical trial in hospitalized patients with T2D and glucose >140 mg/dL on admission was performed. A total of 54 patients were randomized to receive insulin LM75/25 or glargine. In both groups, a correction dose of lispro was administered before meals. Insulin dose was adjusted to obtain a mean blood glucose (BG) between 100 and 140 mg/dL. Results: Improvement in the mean BG after the first day of treatment was similar in both groups (P = 0.470). Glycemic control at the end of follow-up was similar between the group with insulin LM75/25 (131.3 ± 28.4 mg/dL) and insulin glargine (143.8 ± 32.5 mg/dL, P = 0.153). The aim of a BG concentration of <140 mg/dL was obtained in 72% of the patients in the premixed insulin analogue group and 56% of patients in the basal-plus group (P = 0.239). There was no difference in the frequency of hypoglycemia between groups (7 vs. 10, P = 0.529). Conclusion: Results of this trial indicate that the use of a premixed insulin analogue is as effective and safe as the basal-plus regimen to achieve glycemic control.
KW - Hyperglycemia
KW - Inpatient
KW - Insulin lispro mix 75/25
KW - Premixed insulin analogue
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=84997171597&partnerID=8YFLogxK
U2 - 10.1089/dia.2016.0176
DO - 10.1089/dia.2016.0176
M3 - Artículo
C2 - 27860499
SN - 1520-9156
VL - 18
SP - 705
EP - 712
JO - Diabetes Technology and Therapeutics
JF - Diabetes Technology and Therapeutics
IS - 11
ER -